Patients requiring revisional bariatric surgery will be treated with a standard of care laparoscopic procedure.

Patients requiring revisional bariatric surgery will be treated with the same procedure but performed robotically.

Bariatric Surgery

Robotic Surgery

Using robotic techniques during any revesional bariatric surgery

Robotic bariatric surgery - revisional

Using laparoscopic techniques during any revesional bariatric surgery

Laparoscopic bariatric surgery - revisional

Robotic Versus Laparoscopic Techniques for Revisional Bariatric Surgery

A Randomized Study of Robotic Versus Laparoscopic Techniques for Revisional Bariatric Surgery

Any complication - Complication will be defined by the Clavien-Dindo classification and our primary outcome will be long-term complications higher than grade III. These will include leaks and bleeds.
Only complications related to the procedure, such as therapeutic endoscopy or reoperation will be counted.
3)

Readmission to the center within 30 days of the original procedure

Reinterventions for chronic surgical complications (such as stricture) will be assessed through the bariatric clinic.
Only reintenrtventinos related to the original procedure will be counted.

This is the change in weight from the date of operation 2) 3) 4) 5) Sleep apnea (binary, defined as no need for CPAP)

This is the change in BMI from the date of operation

This is a binary outcome relating to the resolution of diabetes from baseline defined as no need for medication

This is a binary outcome relating to the resolution of hypertension from baseline defined as no need for medication

This is a binary outcome relating to the resolution of sleep apnea from baseline defined as no need for medication

McMaster University

We will randomise 60 patients between robotic (30 patients) and laparoscopic revisional bariatric surgery (30 patients) to evaluate those procedures in terms of perioperative safety, weight loss and comorbidity resolution.

Once consent has been signed, the patient will be assigned to any of the two groups, using a computer-based randomization on REDCap and the patient will be assigned to the corresponding study arm.

The first group was formed of the patients diagnosed hyperemesis gravidarum with dehydration

The control group was formed of the patients who were healthy pregnant women admitted to the clinic just for routine examination without any symptoms

Hyperemesis; Gravidarum, With Dehydration

Kayseri Training and Research Hospital

Endothelial Dysfunction in Hyperemesis Gravidarum

Erdem Sahin

Principal Investigator

Kayseri Education and Research Hospital

Patients on deep brain stimulation for either obsessive-compulsive disorder or major depression, undergoing rechargeable neurostimulator implantation as intervention

Obsessive-compulsive Disorder

Depression

Rechargeable neurostimulators are implanted when the non-rechargeable neurostimulators are end-of-life.

Medtronic Restore Advanced 37713

Rechargeable Neurostimulators in Deep Brain Stimulation for Psychiatric Disorders

Feasibility Study Regarding the Implantation and Use of Rechargeable Neurostimulators in Deep Brain Stimulation for Psychiatric Disorders (Either Obsessive-compulsive Disorder or Major Depression)

Change in mean Yale‐Brown Obsessive Compulsive Scale (Y‐BOCS). Mean Y-BOCS during the first 2 years after intervention minus mean Y-BOCS during the last 2 years before intervention.

Change in Hamilton Depression Rating Scale (HAM‐D). Mean HAM-D during the first 2 years after intervention minus mean HAM-D during the last 2 years before intervention.

Change in Beck Depression Inventory (BDI). Mean BDI during the first 2 years after intervention minus mean BDI during the last 2 years before intervention.

Change in Global Assessment of Functioning (GAF). Mean GAF during the first 2 years after intervention minus mean GAF during the last 2 years before intervention.

Change in Stimulation amplitude as measured in volt. Mean stimulation amplitude during the first 2 years after intervention minus mean stimulation amplitude during the last 2 years before intervention.

Change in Stimulation frequency as measured in hertz Mean stimulation frequency during the first 2 years after intervention minus mean stimulation frequency during the last 2 years before intervention

Stimulation pulse width as measured in seconds. Mean stimulation pulse width during the first 2 years after intervention minus mean stimulation pulse width during the last 2 years before intervention.

Change in stimulation contact configuration as expressed in fraction of patients using a certain contact point as anode or cathode.
Fraction of patients using a certain contact point as cathode or anode during the first 2 years after intervention minus fraction of patients using a certain contact point as cathode or anode during the last 2 years before intervention.

Change in frequency of outpatient clinic contacts at the Psychiatry department. Frequency of outpatient clinic contacts at the Psychiatry department during the first 2 years after intervention minus frequency of outpatient clinic contacts at the Psychiatry department during the last 2 years before intervention.

Change in fraction of hospitalized days at the Psychiatry department. Fraction of hospitalized days at the Psychiatry department during the first 2 years after intervention minus fraction of hospitalized days at the Psychiatry department during the last 2 years before intervention.

Change in frequency of outpatient clinic contacts at the Neurosurgery department.
Frequency of outpatient clinic contacts at the Neurosurgery department during the first 2 years after intervention minus frequency of outpatient clinic contacts at the Neurosurgery department during the last 2 years before intervention.

Change in fraction of hospitalized days at the Neurosurgery department. Fraction of hospitalized days at the Neurosurgery department during the first 2 years after intervention minus fraction of hospitalized days at the Neurosurgery department during the last 2 years before intervention.

Change in frequency of neurosurgical procedures related to the DBS system. Frequency of neurosurgical procedures related to the DBS system after intervention minus frequency of neurosurgical procedures related to the DBS system before intervention.

Universitaire Ziekenhuizen Leuven

Medtronic

Part A: RG7388 as a single agent; given at a starting dose of 100 mg each day for five days for the first cycle which will be 56 days.
Part B: combination of RG7388 and Pegasys if subject does not achieve at least a PR by the end of 3 cycles of single agent RG7388

Polycythemia Vera

Essential Thrombocythemia

RG7388 is supplied as film-coated tablets at dosage strengths of 50 mg, 200 mg, 300mg and 400 mg.

RG7388

PEGASYS is supplied as a clear, sterile solution for subcutaneous (SQ) injection available in prefilled syringes. weekly doses at 45ug subcutaneously

Pegasys

Georgetown University Medical Center

Icahn School of Medicine at Mount Sinai

Wake Forest University Baptist Medical Center

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Open Label Phase I Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia (With Pilot Feasibility Study in Combination With Pegylated Interferon Alfa 2a for Patients Who do Not Respond to the Single Agent at Each Dose Level)

John Mascarenhas

Associate Professor

Roche Pharma AG

The Leukemia and Lymphoma Society

Schizophrenia

Schizoaffective Disorder

Psychosis Not Otherwise Specified

Schizophreniform Disorder

ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose

Ondansetron

Simvastatin added to TAU Simvastatin 20mg taken as once daily dose

Simvastatin

Placebo

Dow University of Health Sciences

Karwan e hayat

Role of Anti-Inflammatory Agents in Patients With Schizophrenia

Study of Role of Anti-Inflammatory Agents in Patients With Schizophrenia

Dr Imran B Chaudhry

Pakistan Institute of Living and Learning

Karwan e Hayat

The H.E.L.P. System is a device composed of multiple modules and their associated disposables which can selectively and continuously remove LDL-cholesterol from plasma by precipitating the LDL-cholesterol with high concentrations of heparin in an acidic buffer and returning the plasma to the patient. Procedure steps:
Flushing the system with normal saline.
Filtering whole blood through a 0.2 micron plasma filter for continuous plasma removal.
Mixing the plasma with an equal volume of acetate buffer containing heparin.
Precipitation of LDL as a complex with heparin.
Removing the LDL-heparin precipitate by continuous circulation through a filter.
Removing heparin with use of a heparin adsorber.
Bicarbonate dialysis and ultrafiltration to produce an LDL-free plasma without excess heparin.
Re-mixing the LDL-free plasma with blood coming from the plasma filter and returning the reconstituted blood to the patient.

H.E.L.P. Secura

Not all sites collected this information.

Gender

Region of Enrollment

The Categories listed in the table are the Adverse Events (or similar) that resulted in death.

Occurence of Death

Adverse Events reported for Cardiovascular disease not directly related to therapy.

Occurrence of Cardiovascular Events and Interventions

Serious Unexpected Adverse Events

This is equatable to the incidence of Cardiovascular AEs.

Frequency and Severity of CHD Symptoms (Angina)

All patients received the same Treatment Arm for this study. Treatments were conducted up to 3 times per week; treatment sessions typ. 2 hours in length.
H.E.L.P. is a device composed of multiple modules and associated disposables to selectively and continuously remove LDL-cholesterol from plasma by precipitating the LDL-cholesterol with high concentrations of heparin in an acidic buffer and returning the plasma to the patient.
Flush system with normal saline;
Filter whole blood through 0.2 micron plasma filter for continuous plasma removal;
Mix plasma with equal volume of acetate buffer containing heparin;
Precipitate LDL as a complex with heparin;
Remove LDL-heparin precipitate by continuous circulation through a filter;
Remove heparin with use of a heparin adsorber;
Bicarbonate dialysis and ultrafiltration to produce LDL-free plasma without excess heparin;
Re-mix LDL-free plasma with blood from plasma filter; return reconstituted blood to patient.

hypercholesterolemia/vomiting

Robotic Versus Laparoscopic Techniques for Revisional Bariatric Surgery

Endothelial Dysfunction in Hyperemesis Gravidarum

Rechargeable Neurostimulators in Deep Brain Stimulation for Psychiatric Disorders

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Role of Anti-Inflammatory Agents in Patients With Schizophrenia

Low-Density Lipoprotein (LDL) Apheresis Using H.E.L.P. Therapy

科学支持的最完整的草药数据库